DE2915254A1 - Neue chemische verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel mit antiviraler wirkung - Google Patents
Neue chemische verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel mit antiviraler wirkungInfo
- Publication number
- DE2915254A1 DE2915254A1 DE19792915254 DE2915254A DE2915254A1 DE 2915254 A1 DE2915254 A1 DE 2915254A1 DE 19792915254 DE19792915254 DE 19792915254 DE 2915254 A DE2915254 A DE 2915254A DE 2915254 A1 DE2915254 A1 DE 2915254A1
- Authority
- DE
- Germany
- Prior art keywords
- deoxy
- deoxyuridine
- groups
- compound
- bromovinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims description 49
- 230000000840 anti-viral effect Effects 0.000 title claims description 18
- 238000000034 method Methods 0.000 title claims description 14
- 238000004519 manufacturing process Methods 0.000 title description 10
- 229940126601 medicinal product Drugs 0.000 title 1
- -1 2-iodovinyl Chemical group 0.000 claims description 35
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 125000006239 protecting group Chemical group 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 6
- 241000700584 Simplexvirus Species 0.000 claims description 5
- 239000007795 chemical reaction product Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 3
- 125000004665 trialkylsilyl group Chemical group 0.000 claims description 3
- PDWIQYODPROSQH-PYHARJCCSA-N 2-deoxy-D-ribofuranose Chemical class OC[C@H]1OC(O)C[C@@H]1O PDWIQYODPROSQH-PYHARJCCSA-N 0.000 claims description 2
- 241000335654 Uracis Species 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 229940035893 uracil Drugs 0.000 claims description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 29
- 241000700605 Viruses Species 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 20
- 238000004113 cell culture Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 125000002348 vinylic group Chemical group 0.000 description 11
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- LOLNFJHUEIDGNH-PIXDULNESA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[(e)-2-iodoethenyl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\I)=C1 LOLNFJHUEIDGNH-PIXDULNESA-N 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 208000009889 Herpes Simplex Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- FQRIBMHYAICHAB-DJLDLDEBSA-N 5-(1-chloroethenyl)-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(Cl)=C)=C1 FQRIBMHYAICHAB-DJLDLDEBSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 210000003292 kidney cell Anatomy 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical class ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- YAAQOXBNCODRSI-DJLDLDEBSA-N 5-ethenyl-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=C)=C1 YAAQOXBNCODRSI-DJLDLDEBSA-N 0.000 description 2
- CDEURGJCGCHYFH-DJLDLDEBSA-N 5-ethynyl-2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C#C)=C1 CDEURGJCGCHYFH-DJLDLDEBSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000001399 anti-metabolic effect Effects 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 description 2
- MDHYEMXUFSJLGV-UHFFFAOYSA-N beta-phenethyl acetate Natural products CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- BLXGZIDBSXVMLU-OWOJBTEDSA-N 5-[(e)-2-bromoethenyl]-1h-pyrimidine-2,4-dione Chemical compound Br\C=C\C1=CNC(=O)NC1=O BLXGZIDBSXVMLU-OWOJBTEDSA-N 0.000 description 1
- KTZDXHJATZVCLY-OWOJBTEDSA-N 5-[(e)-2-iodoethenyl]-1h-pyrimidine-2,4-dione Chemical compound I\C=C\C1=CNC(=O)NC1=O KTZDXHJATZVCLY-OWOJBTEDSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101150095130 URAD gene Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- FHYDIJDYCBQDHH-UHFFFAOYSA-N chloroform propan-2-ol Chemical compound C(Cl)(Cl)Cl.CC(C)O.CC(C)O FHYDIJDYCBQDHH-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000011968 lewis acid catalyst Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
und deren Herstellung, die sich als Wirkstoffe in Arzneimitteln, insbesondere für die Behandlung von Virus-Infektionen verwenden lassen, und umfaßt auch Verbindungen, die
als Zwischenprodukte bei der chemischen Synthese dieser
neuen Wirkstoffe brauchbar sind.
E-5- (2-Jodvinyl) -2 · -desoxyuridin. Diese neuen chemischen
Verbindungen lassen sich durch folgende Strukturformel,
worin Hai vorzugsweise Brom oder Jod bedeutet, veranschau-Ii chen:
ä
ID50 | (/ug/nl) | Herpes simplex-1 Stamm KOS (HSP) |
|
Vaccini a (PRK) |
Vaccinia (HSF) |
Herpes simplex-1 Starten KOS (PRK) |
0,07 |
0,4 | 0,1 | 0,04 | 2 |
0,4 | 0,7 | 0,4 | 0,007 |
7 | 0,7 | 0,007 | - |
10 | - | 0,01 | 0,4 |
0,2 | 0,1 | 0,07 | |
gebnisse sind in Tabelle 3 angegeben.
nach der Behandlung mit E-5-(2-Bromvtnyl)-2 '-desoxyurldin und verwandten Verbindungen bestimmt. In Anwesenheit von unterschiedlichen Konzentrationen der Verbindungen ( im
Bereich von 0,01 bis 100 .ug/ml ) wurden die Zellen auf
Kunststoff-Petrischalen ( Durchmesser: 55 mm ) in einer
Tabelle 3 veranschaulicht. Der TD -Wert gibt die Inhibierungsdosis-50 an, das ist die Konzentration an Verbindung, die erforderlich ist, um die Gesamt-Zellzahl um
50% zu vermindern.
2O | 8 | 8 |
27 | <6 | 2 |
70 | 35 | >33 |
100 | «6 | 0,3 |
Claims (8)
- DIPL. PHYS.K. SCHAEFER DATUM 2915254UNSER ZEICHEN: PATENTANWÄLTE SCHAEFER. POSTFACH 70 1542, D-2 HAMBURG 7ff lHRZEICHEN: ΑΤ)Τ1 1 19 79Stichting Rega V.Z.W., No. 3, Krakenstraat, B-3000 Leuven, BelgienPatentansprücheNeue chemische Verbindungen, bestehend aus einem E-5-(2-Halogenviny1)-2'-desoxyurldl η.
- 2. Verbindung nach Anspruch 1, bestehend aus E-5- (2 -Bromvi ny 1) -2 ' -desoxy uri di η.
- 3. Verbindung nach Anspruch 1, bestehend aus E-5-(2-Jodvinyl)-2'-desoxy uri din.
- 4. Verfahren zur Herstellung einer Verbindung nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß man ein geschützte Hydroxylgruppen aufweisendes reaktives Derivat von 2-Desoxy-D-erythro-pentofuranose mit einem Bis-(trialkyU-silyl-Deri vat von E-5-(2-Halogenvinyl)-uracil umsetzt und von dem Umsetzungsprodukt die Trialkylsilylgruppen und die Schutzgruppen an den Hydroxylgruppen entfernt.
- 5. Verfahren nach Anspruch 4, dadurch gekennzeichnet, daß man das Umsetzungsprodukt, bevor man von den Hydroxylgruppen die Schutzgruppen entfernt, in seine Anomeren zerlegt und das ß-Anomer gewinnt.
- 6. Verfahren nach Anspruch 4, dadurch gekennzeichnet, daß raan das Umsetzungsprodukt, nachdem man von den Hydroxylgruppen die Schutzgruppen entfernt hat, in seine Anomeren zerlegt und das ß-Anomer gewinnt.
- 7. Arzneimittel mit antiviraler Wirkung, insbesondere geeignet für die Behandlung von durch das Virus Herpes simplex verursachte Infektionen, dadurch gekennzeichnet, daß darin909846/0581als Wirkstoff eine Verbindung der Ansprüche 1 bis 3 zusammen mit für die anwendungs fertige Darreichungsform üblichen Zusatzstoffen enthalten ist.
- 8. Neue chemische Verbindung, bestehend aus einem Bis-(trialkyl)-silyl-Derivat eines E-5-(2-Halogenvinyl) uraci Is.9098 46/058
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB16158/78A GB1601020A (en) | 1978-04-24 | 1978-04-24 | 2'-deoxy-5 (2-halogenovinyl)-uridines |
Publications (2)
Publication Number | Publication Date |
---|---|
DE2915254A1 true DE2915254A1 (de) | 1979-11-15 |
DE2915254C2 DE2915254C2 (de) | 1990-07-12 |
Family
ID=10072234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19792915254 Granted DE2915254A1 (de) | 1978-04-24 | 1979-04-14 | Neue chemische verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel mit antiviraler wirkung |
Country Status (11)
Country | Link |
---|---|
US (1) | US4424211A (de) |
JP (1) | JPS554364A (de) |
BE (1) | BE875773A (de) |
CA (1) | CA1117108A (de) |
CH (1) | CH643273A5 (de) |
DE (1) | DE2915254A1 (de) |
FR (1) | FR2432526A1 (de) |
GB (1) | GB1601020A (de) |
IT (1) | IT1165954B (de) |
NL (1) | NL192793C (de) |
SE (1) | SE445832B (de) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0031128A1 (de) * | 1979-12-19 | 1981-07-01 | Yamasa Shoyu Kabushiki Kaisha | (E)-5-(2-Halogenvinyl)-arabinfuransyluracil, Verfahren zu seiner Herstellung und seine Verwendungen |
EP0049110A1 (de) * | 1980-10-01 | 1982-04-07 | Beecham Group Plc | Antiviral-Verbindungen, ihre Herstellung und ihre Verwendung |
EP0060099A1 (de) * | 1981-03-11 | 1982-09-15 | Beecham Group Plc | Antivirale Verbindungen, ihre Herstellung und Verwendung |
EP0061283A1 (de) * | 1981-03-20 | 1982-09-29 | Beecham Group Plc | Antivirale Verbindungen, ihre Herstellung und Anwendung |
EP0072137A1 (de) * | 1981-08-01 | 1983-02-16 | Beecham Group Plc | Antivirale Deoxyuridin-Derivate |
FR2513252A1 (fr) * | 1981-09-07 | 1983-03-25 | Egyt Gyogyszervegyeszeti Gyar | (e)-5-(2-bromovinyl)-uridine, ses derives et leur procede de preparation |
EP0095292A1 (de) * | 1982-05-22 | 1983-11-30 | Beecham Group Plc | 5-(2-Halovinyl)-2'-deoxyuridin-Derivate, Verfahren zu ihrer Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und ihre Anwendung bei der Behandlung von viralen Infektionen |
EP0095294A1 (de) * | 1982-05-22 | 1983-11-30 | Beecham Group Plc | Deoxyuridin-Derivate, ihre Herstellungsverfahren und ihre medizinische Anwendung |
EP0097039A1 (de) * | 1982-06-16 | 1983-12-28 | Beecham Group Plc | 5-(E-2-Halovinyl)-2'-deoxyuridin-Derivate, Verfahren zur Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und ihre Anwendung bei der Behandlung von viralen Infektionen |
FR2531437A1 (fr) * | 1982-08-04 | 1984-02-10 | Mta Koezponti Kemiai Kutato In | Procede de preparation de la 5-(e)-(2-bromovinyl)-2'-desoxyuridine et de ses derives, derives de 5-(e)-(2-bromovinyl)-2'-desoxyuridine et medicaments les contenant |
FR2531962A1 (fr) * | 1982-08-17 | 1984-02-24 | Sandoz Sa | Nouveaux derives de la desoxyuridine, leur preparation et leur utilisation comme medicaments |
EP0104066A2 (de) * | 1982-09-17 | 1984-03-28 | Glaxo Group Limited | Derivate von 5-Halovinyl-2'-deoxyuridin |
EP0104857A1 (de) * | 1982-09-28 | 1984-04-04 | Beecham Group Plc | Deoxyuridin-Derivate, Verfahren zu deren Herstellung und ihre Verwendung in der Medizin |
WO1988004662A1 (en) * | 1986-12-19 | 1988-06-30 | Astra Läkemedel Aktiebolag | Use of nucleosides for the manufacture of medicament for treatment of diseases caused by retrovirus or hepatitis b virus |
US5215971A (en) * | 1986-12-19 | 1993-06-01 | Medivir Ab | Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides |
WO2002068443A1 (en) * | 2001-02-28 | 2002-09-06 | Menarini Ricerche S.P.A. | Process for the preparation of (e)-5-(2-bromovinyl)-2'-deoxyuridine |
EP3792271A1 (de) | 2019-09-13 | 2021-03-17 | Aurobindo Pharma Limited | Verfahren zur herstellung von brivudin |
WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0082667A1 (de) * | 1981-12-18 | 1983-06-29 | Beecham Group Plc | Pharmazeutische Zusammensetzungen |
DE3362994D1 (en) * | 1982-02-12 | 1986-05-22 | Atomic Energy Authority Uk | Laser pipe welder/cutter |
US4658044A (en) * | 1983-09-16 | 1987-04-14 | Glaxo Group Limited | Intermediates for uracil derivatives |
JPS62500239A (ja) * | 1984-09-24 | 1987-01-29 | ピイシーアール,インコーポレイテッド | 2−デオキシウリジンの製造方法 |
GB8517402D0 (en) | 1985-07-10 | 1985-08-14 | Wellcome Found | Treatment of viral infections |
GB8629892D0 (en) * | 1986-12-15 | 1987-01-28 | Wellcome Found | Antiviral compounds |
US4863927A (en) * | 1987-05-11 | 1989-09-05 | Merck & Co., Inc. | 1-(2-hydroxymethyl)cycloalkylmethyl)-5-substituted uracils |
JPH0217199A (ja) * | 1988-07-05 | 1990-01-22 | Japan Tobacco Inc | 2’−デオキシ−β−アデノシンの製造方法 |
JPH0217198A (ja) * | 1988-07-05 | 1990-01-22 | Japan Tobacco Inc | 2’−デオキシ−β−シチジン誘導体およびその塩の製造法 |
EP0428623A4 (en) * | 1988-08-10 | 1993-12-08 | Stephen Leslie Sacks | Production of radioiodinated 1--g(b)-d-arabinofuranosyl)-5(e)-(2-iodovinyl)uracil, and uses thereof, and related analogues incorporating alternative halogen radionuclides, the general radiohalogenation precursors, 1-(2,3,5-tri-o-acetyl--g(b)-d-arabinofuranosyl)-5(z and e)-(2-trimethylsilylvinyl)urac |
EA005497B1 (ru) * | 2001-01-03 | 2005-02-24 | Берлин Хеми Аг | Применение фармацевтической композиции, содержащей бривудин, для лечения герпесвирусных инфекций |
JP4651942B2 (ja) * | 2001-12-20 | 2011-03-16 | フアーマセツト・インコーポレイテッド | Ebv及びkhsv感染並びにそれに伴う異常細胞増殖の治療 |
CN102432655A (zh) * | 2011-10-28 | 2012-05-02 | 河南师范大学 | 一种合成5-((e)-2-溴乙烯基)-2′-脱氧尿嘧啶核苷(溴呋啶)的方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU452961A3 (ru) | 1969-04-11 | 1974-12-05 | Шеринг Аг. (Фирма) | Способ получени пиримидиннуклеозидов |
DE2012888C3 (de) | 1970-03-14 | 1981-04-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden |
DE2122991C2 (de) | 1971-05-04 | 1982-06-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden |
US4093715A (en) | 1977-04-28 | 1978-06-06 | Research Corporation | 5-Iodo-5'-amino-2',5'-dideoxycytidine and the pharmaceutically acceptable salts thereof |
US4093716A (en) | 1977-04-28 | 1978-06-06 | Research Corporation | Compositions containing 5-amino-5-deoxythymidine and pharmaceutically acceptable salts thereof |
DE2721466A1 (de) | 1977-05-12 | 1978-11-16 | Robugen Gmbh | Verfahren zur herstellung von 2'-desoxyribofuranosylnucleosiden |
-
1978
- 1978-04-24 GB GB16158/78A patent/GB1601020A/en not_active Expired
-
1979
- 1979-04-14 DE DE19792915254 patent/DE2915254A1/de active Granted
- 1979-04-18 NL NL7903029A patent/NL192793C/nl not_active IP Right Cessation
- 1979-04-19 CH CH367179A patent/CH643273A5/de not_active IP Right Cessation
- 1979-04-23 CA CA000326164A patent/CA1117108A/en not_active Expired
- 1979-04-23 FR FR7910230A patent/FR2432526A1/fr active Granted
- 1979-04-23 SE SE7903541A patent/SE445832B/sv not_active IP Right Cessation
- 1979-04-23 IT IT09403/79A patent/IT1165954B/it active
- 1979-04-23 BE BE1/9368A patent/BE875773A/xx not_active IP Right Cessation
- 1979-04-24 JP JP5133379A patent/JPS554364A/ja active Granted
-
1981
- 1981-12-21 US US06/332,757 patent/US4424211A/en not_active Expired - Lifetime
Non-Patent Citations (4)
Title |
---|
BLEACKLEY R.C. et al.: Synthesis of 5-substituted uracils derived from 5-Acetyluracil, in: Tetrahedron Vol.32, 1976, S.2795-7 * |
PERMAN J. et al.: Synthesis of 1-(2-Deoxy-?-D-erythro-pentofuranosyl)-5-ethynyl-1,2,3,4-tetrahydropyrimidine-2,4-dione (5-Ethynyl-2'-deoxyuridine), in: Tetrahedron Letters No.28, 1976, S.2427-30 |
PERMAN J. et al.: Synthesis of 1-(2-Deoxy-beta-D- erythro-pentofuranosyl)-5-ethynyl-1,2,3,4- tetrahydropyrimidine-2,4-dione (5-Ethynyl-2'- deoxyuridine), in: Tetrahedron Letters No.28, 1976, S.2427-30 * |
US-Z: Proceedings of the National Academy of Science, 76, 2947, 1979 * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0031128A1 (de) * | 1979-12-19 | 1981-07-01 | Yamasa Shoyu Kabushiki Kaisha | (E)-5-(2-Halogenvinyl)-arabinfuransyluracil, Verfahren zu seiner Herstellung und seine Verwendungen |
EP0049110A1 (de) * | 1980-10-01 | 1982-04-07 | Beecham Group Plc | Antiviral-Verbindungen, ihre Herstellung und ihre Verwendung |
EP0060099A1 (de) * | 1981-03-11 | 1982-09-15 | Beecham Group Plc | Antivirale Verbindungen, ihre Herstellung und Verwendung |
EP0061283A1 (de) * | 1981-03-20 | 1982-09-29 | Beecham Group Plc | Antivirale Verbindungen, ihre Herstellung und Anwendung |
EP0072137A1 (de) * | 1981-08-01 | 1983-02-16 | Beecham Group Plc | Antivirale Deoxyuridin-Derivate |
FR2513252A1 (fr) * | 1981-09-07 | 1983-03-25 | Egyt Gyogyszervegyeszeti Gyar | (e)-5-(2-bromovinyl)-uridine, ses derives et leur procede de preparation |
EP0095292A1 (de) * | 1982-05-22 | 1983-11-30 | Beecham Group Plc | 5-(2-Halovinyl)-2'-deoxyuridin-Derivate, Verfahren zu ihrer Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und ihre Anwendung bei der Behandlung von viralen Infektionen |
EP0095294A1 (de) * | 1982-05-22 | 1983-11-30 | Beecham Group Plc | Deoxyuridin-Derivate, ihre Herstellungsverfahren und ihre medizinische Anwendung |
EP0097039A1 (de) * | 1982-06-16 | 1983-12-28 | Beecham Group Plc | 5-(E-2-Halovinyl)-2'-deoxyuridin-Derivate, Verfahren zur Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und ihre Anwendung bei der Behandlung von viralen Infektionen |
FR2531437A1 (fr) * | 1982-08-04 | 1984-02-10 | Mta Koezponti Kemiai Kutato In | Procede de preparation de la 5-(e)-(2-bromovinyl)-2'-desoxyuridine et de ses derives, derives de 5-(e)-(2-bromovinyl)-2'-desoxyuridine et medicaments les contenant |
DE3328238A1 (de) * | 1982-08-04 | 1984-02-23 | Akademie der Wissenschaften der DDR, DDR 1115 BERLIN | (e)-5-(2''-bromvinyl)-3',5'-di-(o-acyl)-2'-desoxyuridine, verfahren zur herstellung derselben beziehungsweise von (e)-5-(2''-bromvinyl)-2'-desoxyuridin und die ersteren enthaltende arzneimittel |
WO1984000759A1 (en) * | 1982-08-17 | 1984-03-01 | Sandoz Ag | Desoxyuridine derivatives, processes for their preparation and their use as pharmaceuticals |
FR2531962A1 (fr) * | 1982-08-17 | 1984-02-24 | Sandoz Sa | Nouveaux derives de la desoxyuridine, leur preparation et leur utilisation comme medicaments |
EP0104066A2 (de) * | 1982-09-17 | 1984-03-28 | Glaxo Group Limited | Derivate von 5-Halovinyl-2'-deoxyuridin |
EP0104066A3 (en) * | 1982-09-17 | 1984-06-06 | Glaxo Group Limited | 5-halovinyl-2'-deoxyuridine derivatives |
EP0104857A1 (de) * | 1982-09-28 | 1984-04-04 | Beecham Group Plc | Deoxyuridin-Derivate, Verfahren zu deren Herstellung und ihre Verwendung in der Medizin |
WO1988004662A1 (en) * | 1986-12-19 | 1988-06-30 | Astra Läkemedel Aktiebolag | Use of nucleosides for the manufacture of medicament for treatment of diseases caused by retrovirus or hepatitis b virus |
US5215971A (en) * | 1986-12-19 | 1993-06-01 | Medivir Ab | Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides |
WO2002068443A1 (en) * | 2001-02-28 | 2002-09-06 | Menarini Ricerche S.P.A. | Process for the preparation of (e)-5-(2-bromovinyl)-2'-deoxyuridine |
US6864366B2 (en) | 2001-02-28 | 2005-03-08 | Menarini Richerche S.P.A. | Process for the preparation of (e)-5-(2-bromovinyl)-2′-deoxyuridine |
CZ299318B6 (cs) * | 2001-02-28 | 2008-06-18 | Menarini Ricerche S. P. A. | Zpusob výroby (E)-5-(2-bromvinyl)-2´-deoxyuridinu |
HRP20030671B1 (en) * | 2001-02-28 | 2011-11-30 | Menarini Ricerche S.P.A. | Process for the preparation of (e)-5-(2-bromvinil)-2'-deoxyuridine |
EP3792271A1 (de) | 2019-09-13 | 2021-03-17 | Aurobindo Pharma Limited | Verfahren zur herstellung von brivudin |
WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
Also Published As
Publication number | Publication date |
---|---|
SE7903541L (sv) | 1979-10-25 |
CH643273A5 (de) | 1984-05-30 |
NL7903029A (nl) | 1979-10-26 |
IT1165954B (it) | 1987-04-29 |
BE875773A (nl) | 1979-10-23 |
GB1601020A (en) | 1981-10-21 |
FR2432526A1 (fr) | 1980-02-29 |
NL192793C (nl) | 1998-02-03 |
FR2432526B1 (de) | 1982-10-08 |
JPS642599B2 (de) | 1989-01-18 |
DE2915254C2 (de) | 1990-07-12 |
JPS554364A (en) | 1980-01-12 |
NL192793B (nl) | 1997-10-01 |
SE445832B (sv) | 1986-07-21 |
US4424211A (en) | 1984-01-03 |
CA1117108A (en) | 1982-01-26 |
IT7909403A0 (it) | 1979-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2915254A1 (de) | Neue chemische verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel mit antiviraler wirkung | |
EP0484333B1 (de) | Nucleosid-derivate und deren verwendung als arzneimittel | |
AT390000B (de) | Verwendung von 3'-azido-3'-desoxythymidin oder eines pharmazeutisch annehmbaren derivats hievon zur herstellung von medikamenten | |
DE69318836T2 (de) | 1,5-anhydrohexitolnukleosidanaloge und pharmazeutische verwendung davon | |
DE60005501T2 (de) | 4'-c-ethynyl-pyrimidine nukleoside | |
DE3036131C2 (de) | ||
WO1993016092A1 (de) | Neue lipidphosphonsäure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel | |
DE3887014T2 (de) | Nukleoside, ihre Herstellung und pharmazeutische Zusammenstellungen. | |
DE2455423C3 (de) | 28.11.73 Japan 132796-73 26.04.74 Japan 46617-74 In 1-Stellung acylierte 5-Fluoruracile und Arzneimittel aus diesen Verbindungen und üblichen inerten Bindemitteln oder Trägermaterialien | |
DE3543346A1 (de) | Neue nucleosidderivate und verfahren zu ihrer herstellung | |
DE3390162T1 (de) | Desoxyuridinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Pharmazeutika | |
DE69126469T2 (de) | Pyrimidin-Nukleosid-Derivate und antivirale Mittel, die diese Derivate als aktiven Bestandteil enthalten | |
DD255351A5 (de) | Verfahren zur herstellung von carbocyclischen purinnucleosiden | |
EP0255894B1 (de) | Pyrimidinderivate, deren Herstellung und Arzneimittel, die diese Derivate enthalten | |
DE3508356C2 (de) | ||
CH639274A5 (de) | Antikrebsmittel. | |
DE2639135C2 (de) | 1-Alkylcarbamoyl-5-Fluoruracil-Derivate, ihre Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
DE2310329A1 (de) | Arabinofuranosylcytosine und verfahren zu ihrer herstellung | |
DE3781879T2 (de) | Anthracyclinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel. | |
DE3233198A1 (de) | (e)-5-(2''-(brom)-vinyl)-uridine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
DE68917060T2 (de) | 2'-Methylidenpyrimidin-Nukleoside, ihre Verwendung und Verfahren zu ihrer Herstellung. | |
DE3820588C2 (de) | ||
DE69008085T2 (de) | Oxetanocinderivate, ihre Salze und ihre Verwendung. | |
DE69424475T2 (de) | Verfahren zur Herstellung von 1-(2'-deoxy-beta-D-erythropentofuranosyl)-5-trifluormethyluracil Derivaten | |
DE2817923C2 (de) | Septacidinverbindungen und diese enthaltende Arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8110 | Request for examination paragraph 44 | ||
8128 | New person/name/address of the agent |
Representative=s name: SCHOENWALD, K., DR.-ING. VON KREISLER, A., DIPL.-C |
|
D2 | Grant after examination | ||
8364 | No opposition during term of opposition | ||
V448 | Application of spc |
Free format text: PRODUCT NAME: E-5-(2-BROMVINYL)-2`-DESOXYURIDIN BRIVUDIN; REGISTRATION NO/DATE: 15/04/556, 19900423 Spc suppl protection certif: 193 75 022 Filing date: 19930514 |
|
8327 | Change in the person/name/address of the patent owner |
Owner name: BERLIN - CHEMIE AG, 12489 BERLIN, DE |
|
V457 | Spc granted |
Free format text: PRODUCT NAME: E-5-(2-BROMVINYL)-2`-DESOXYURIDIN BRIVUDIN; REGISTRATION NO/DATE: 15/04/556, 19900423 Spc suppl protection certif: 193 75 022 Filing date: 19930514 |
|
V464 | Spc expired |
Free format text: PRODUCT NAME: E-5-(2-BROMVINYL)-2`-DESOXYURIDIN BRIVUDIN; REGISTRATION NO/DATE: 15/04/556, 19900423 Spc suppl protection certif: 193 75 022 Filing date: 19930514 |